Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05692596 · ClinicalTrials.gov registry record
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
A clinical trial of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- 317
- Enrollment target
- 1
- Study location
NCT05692596: Active study of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05692596 is a study of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 317 participants, below the 597-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05692596, a study of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 317 participants
- Enrollment target
- 1
- Study location
Study Summary
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
Primary Outcome
A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.
Conditions Studied
Interventions
- OTHER Data collection
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2026-07 |
What the registry record for NCT05692596 still lists
NCT05692596 is an observational study that tracks outcomes without assigning an intervention. The registered 317 participants enrollment target is mid-sized for trials with a published cap, below the 597-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (47% lower).
The record links to 10 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.
NCT05692596 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05692596 about?
NCT05692596 is a clinical study titled "The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics". The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
What is the current status of trial NCT05692596?
This trial is currently active not recruiting. The enrollment target is 317 participants. The study started on 2022-10-06. Estimated completion is 2026-07.
What conditions does trial NCT05692596 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, Lynch Syndrome, Pancreatic Cyst, BRCA Mutation.
What interventions are being tested in trial NCT05692596?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT05692596?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05692596 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05692596's enrollment target sits among peer trials
317 19th of 84 higher than 66 of 84 other Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04594642 · 317 participants · Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- NCT04977453 · 317 participants · Phase 1
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- NCT05137054 · 317 participants · Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- NCT05382754 · 317 participants · NA
Home Apnea Testing in CHildren Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI